Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia
Position
Senior Vice President
Company
Royalty Pharma plc
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Royalty Pharma has appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be responsible for leading the company's royalty business in Asia and will be based in Hong Kong.
Quick answer
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia (March 3, 2026). Royalty Pharma plc is based in New York, New York, United States.
- Who is the new Senior Vice President at Royalty Pharma plc?
- Royalty Pharma plc named Kenneth Sun Senior Vice President, announced March 3, 2026.
- What did Royalty Pharma plc announce on March 3, 2026?
- Royalty Pharma has appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be responsible for leading the company's royalty business in Asia and will be based in Hong Kong.
- What does Royalty Pharma plc do?
- Royalty Pharma plc is a pharmaceutical company with a robust EBITDA of $2.57 billion and market capitalization of $11.64 billion.
- Where is Royalty Pharma plc based?
- Royalty Pharma plc is based in New York, New York, United States.
- Which similar companies made leadership changes around the same time?
- Santhera Pharmaceuticals (March 10, 2026), MBX Biosciences, Inc. (March 10, 2026), Aquestive Therapeutics, Inc. (February 18, 2026) and Atossa Therapeutics (March 19, 2026) also announced leadership changes within 45 days of Royalty Pharma plc.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Pharmaceutical
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Santhera Pharmaceuticals Appoints Marc Clausse as Chief Commercial Officer (March 10, 2026)
- MBX Biosciences Appoints Karen Basbaum as Chief Business Officer (March 10, 2026)
- Aquestive Therapeutics Appoints Dr. Matthew Greenhawt as Chief Medical Officer (February 18, 2026)
- Atossa Therapeutics Appoints Kathy Puyana Theall and Adebola Giwa as Medical Directors (March 19, 2026)
- Aurinia Pharmaceuticals Appoints Kevin Tang as Chief Executive Officer and Ryan Cole as Chief Operating Officer (March 23, 2026)
- Bristol Myers Squibb Appoints Harald Hampel as Senior VP Worldwide Head of Medical Affairs. (February 9, 2026)
Who to call at Royalty Pharma plc, and when
A new leader at Royalty Pharma plc brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Royalty Pharma plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Royalty Pharma plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Royalty Pharma plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Royalty Pharma plc changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Royalty Pharma plc changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.